Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Oncolytics Biotech (ONCY) is back on investors' radars after ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In one of the most far-reaching changes to Pakistan's higher education admission system in recent years, Higher Education Commission Pakistan has centralised the MPhil and PhD admission process by ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

CUMMINGTON — Bill Adams looks out onto what once was an artificially formed pond on Stage Road in Cummington. For years, a small culvert prevented full water flow from the North Branch Swift River, a ...

The Higher Education Commission of Pakistan (HEC) on Monday announced the launch of a “fully online and paperless” degree attestation system to facilitate students. In December last year, the HEC said ...

Florida-Based AP Governance Firm Selected as RFP-Stage Contender, Reinforcing Its Authority in Enterprise SAP Vendor Master Data Compliance and Modernization PORT ST. LUCIE, Fla., May 10, 2026 / PRZen ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...